BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 233 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $37,217,213 | -20.6% | 5,286,536 | -5.9% | 0.04% | -25.4% |
| Q1 2023 | $46,857,222 | +77125.3% | 5,618,372 | +6.3% | 0.06% | -33.0% |
| Q4 2022 | $60,676 | -99.9% | 5,285,348 | +9.8% | 0.09% | -2.2% |
| Q3 2022 | $60,653,000 | -5.2% | 4,813,772 | -20.4% | 0.09% | +1.1% |
| Q2 2022 | $63,977,000 | -23.0% | 6,046,961 | +18.4% | 0.09% | -5.3% |
| Q1 2022 | $83,038,000 | +18.6% | 5,106,903 | +1.0% | 0.09% | +34.3% |
| Q4 2021 | $70,015,000 | +40606.4% | 5,055,264 | +42150.4% | 0.07% | – |
| Q3 2021 | $172,000 | – | 11,965 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |